Cargando…
The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
BACKGROUND: Treatment of severe asthma may include high dose systemic-steroid therapy which is associated with substantial additional morbidity. This study estimates the additional healthcare costs associated with steroid-induced morbidity by comparing three patients groups: those with severe asthma...
Autores principales: | Barry, L. E., Sweeney, J., O’Neill, C., Price, D., Heaney, L. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485660/ https://www.ncbi.nlm.nih.gov/pubmed/28651591 http://dx.doi.org/10.1186/s12931-017-0614-x |
Ejemplares similares
-
Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma
por: Gurnell, M., et al.
Publicado: (2021) -
Adverse perception of cough in patients with severe asthma: a discrete choice experiment
por: Holmes, Joshua, et al.
Publicado: (2023) -
Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma
por: Voorham, Jaco, et al.
Publicado: (2018) -
Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
por: Gallagher, Nicola E., et al.
Publicado: (2018) -
Oral Corticosteroids Tapering in Severe Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2021)